US/China venture Ascletis' two-pronged strategy off to a well-funded start
This article was originally published in Scrip
Some start-ups may be content with raising $10 million from investors in their initial round of funding. Not so Ascletis, which set its sights somewhat higher – 10 times higher in fact.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.